Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur(R)), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome

Author: Regidor P.-A.   Regidor M.   Kato K.   Bier U.W.   Buhler K.   Schindler A.E.  

Publisher: Elsevier

ISSN: 0301-2115

Source: European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol.73, Iss.2, 1997-06, pp. : 153-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract